JP2018062532A5 - - Google Patents

Download PDF

Info

Publication number
JP2018062532A5
JP2018062532A5 JP2018010718A JP2018010718A JP2018062532A5 JP 2018062532 A5 JP2018062532 A5 JP 2018062532A5 JP 2018010718 A JP2018010718 A JP 2018010718A JP 2018010718 A JP2018010718 A JP 2018010718A JP 2018062532 A5 JP2018062532 A5 JP 2018062532A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administration
specific promoter
cell type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018010718A
Other languages
English (en)
Japanese (ja)
Other versions
JP6440875B2 (ja
JP2018062532A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018062532A publication Critical patent/JP2018062532A/ja
Publication of JP2018062532A5 publication Critical patent/JP2018062532A5/ja
Application granted granted Critical
Publication of JP6440875B2 publication Critical patent/JP6440875B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018010718A 2013-10-29 2018-01-25 酸化ストレスを阻害するための方法および組成物 Active JP6440875B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896805P 2013-10-29 2013-10-29
US61/896,805 2013-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016526853A Division JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018217337A Division JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2018062532A JP2018062532A (ja) 2018-04-19
JP2018062532A5 true JP2018062532A5 (enExample) 2018-06-07
JP6440875B2 JP6440875B2 (ja) 2018-12-19

Family

ID=53005074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016526853A Active JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物
JP2018010718A Active JP6440875B2 (ja) 2013-10-29 2018-01-25 酸化ストレスを阻害するための方法および組成物
JP2018217337A Pending JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016526853A Active JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018217337A Pending JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Country Status (4)

Country Link
US (3) US10980896B2 (enExample)
EP (3) EP4331590A3 (enExample)
JP (3) JP6317440B2 (enExample)
WO (1) WO2015066190A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331590A3 (en) 2013-10-29 2024-04-17 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
RU2651757C2 (ru) * 2016-01-19 2018-04-23 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена sod2 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, связанных с оксидативным стрессом, способ получения и использования
RU2653491C2 (ru) * 2016-01-20 2018-05-08 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена gpx1 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, связанных с оксидативным стрессом, способ получения и использования
RU2651758C2 (ru) * 2016-01-20 2018-04-23 Селл энд Джин Терапи Лтд Средство для коррекции патологических состояний клеток органов и тканей и/или органов и тканей человека, на основе гена gpx3, связанных с оксидативным стрессом, способ получения и использования
RU2649820C2 (ru) * 2016-01-20 2018-04-04 Селл энд Джин Терапи Лтд Средство для коррекции патологических состояний клеток органов и тканей и/или органов и тканей человека на основе гена col1a2, связанных с количественным снижением белка альфа-2 цепи коллагена i типа
WO2017136805A1 (en) * 2016-02-06 2017-08-10 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
RU2651048C1 (ru) * 2016-11-21 2018-04-18 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена il-11 и/или уменьшением количества белка интерлейкина-11 на основе генно-терапевтических субстанций с геном il-11, способ получения и использования
RU2653487C1 (ru) * 2016-11-30 2018-05-08 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена lif и/или уменьшением количества белка фактора, ингибирующего лейкемию, на основе генно-терапевтических субстанций с геном lif, способ получения и использования
RU2649814C1 (ru) * 2017-02-14 2018-04-04 Общество с ограниченной ответственностью "Медсервис" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена сат и/или уменьшением активности белка каталазы на основе генно-терапевтических субстанций с геном сат, способ получения и использования
JP7105532B2 (ja) * 2017-05-10 2022-07-25 ロート製薬株式会社 後眼部疾患の予防、改善、又は治療用組成物
FI3684423T3 (fi) * 2017-09-20 2023-06-15 4D Molecular Therapeutics Inc Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
CA3095911A1 (en) * 2018-04-03 2019-10-10 Cornell University Gene therapy for oxidative stress
WO2020041169A2 (en) 2018-08-20 2020-02-27 Janssen Pharmaceutica Nv Inhibitors of keap1-nrf2 protein-protein interaction
CN109055428A (zh) * 2018-09-19 2018-12-21 上海市第人民医院 一种重组腺相关病毒载体及其制备方法与应用
WO2020132040A1 (en) * 2018-12-20 2020-06-25 President And Fellows Of Harvard College Compositions and methods for the treatment of degenerative ocular diseases
US20220118107A1 (en) * 2019-02-11 2022-04-21 President And Fellows Of Harvard College Txnip and ldhb compositions and methods for the treatment of degenerative ocular diseases
MX2022013411A (es) 2020-04-27 2022-11-14 4D Molecular Therapeutics Inc Genes gla con codones optimizados y usos de los mismos.
WO2021226037A1 (en) * 2020-05-04 2021-11-11 Sulfagenix, Inc. Treatment of viral infections
WO2021250081A1 (en) * 2020-06-09 2021-12-16 Genethon Nrf2 activator for use in treating dilated cardiomyopathies
KR102620997B1 (ko) * 2022-11-10 2024-01-04 주식회사 아이두젠 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물
WO2025110266A1 (ko) * 2023-11-21 2025-05-30 주식회사 퓨어바이오 시력 보호 또는 망막 질환의 개선, 예방 또는 치료를 위한 노각나무 추출물의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4598049A (en) 1983-08-31 1986-07-01 Systec Inc. General purpose gene synthesizer
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
CA1336396C (en) 1988-07-25 1995-07-25 Kiyoshi Kita Intraocular anticoagulant including antithrombin iii and method of administration
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH09505557A (ja) 1993-09-03 1997-06-03 アメリカ合衆国 ヒト腫瘍細胞の遺伝子形質転換によるヒト腫瘍の治療
US5763217A (en) 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5763242A (en) 1995-02-08 1998-06-09 Thomas Jefferson University Method for increasing transduction efficiency of recombinant retroviral vectors
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO2000054595A1 (en) 1999-03-15 2000-09-21 John Guy Recombinant adeno-associated virus transfer of genes affecting demyelination
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20080274093A1 (en) * 2004-12-02 2008-11-06 Johnson Jeffrey A Method of diminishing the symptoms of neurodegenerative disease
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20100041741A1 (en) 2006-10-23 2010-02-18 John Guy Suppression of mitochondrial oxidative stress
PT2137537E (pt) 2007-02-08 2013-08-22 Biogen Idec Inc Composições e respectivas utilizações para o tratamento da esclerose múltipla
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
CA2755409C (en) * 2009-03-16 2019-04-30 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
WO2010121010A2 (en) 2009-04-16 2010-10-21 President And Fellows Of Harvard College Methods for inhibiting starvation of a cell
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
EP4331590A3 (en) 2013-10-29 2024-04-17 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
WO2018200542A1 (en) * 2017-04-24 2018-11-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders

Similar Documents

Publication Publication Date Title
JP2018062532A5 (enExample)
JP2016535034A5 (enExample)
JP2022141670A5 (enExample)
HRP20211024T1 (hr) Aav vektori za gensku terapiju mrežnice i cns-a
Liu et al. Gene therapy for ocular diseases
JP2017518271A5 (enExample)
JP2019518427A5 (enExample)
FI3795181T3 (fi) Amd:n hoito aav2-variantilla ja afliberseptillä
JP2018510620A5 (enExample)
JP2020528734A5 (enExample)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
HRP20201831T1 (hr) Optimizirani promoter rpe65 i kodirajuće sekvence
JP2018508519A5 (enExample)
HRP20201225T1 (hr) Terapije poboljšavanja gena kod nasljedne degeneracije mrežnice uzrokovanu mutacijama u genu prpf31
CA2995656A1 (en) Treatment of retinitis pigmentosa
WO2022221404A3 (en) Adeno-associated virus compositions having increased brain enrichment
JP2022529782A (ja) シュタルガルト病（ａｂｃａ４）の遺伝子治療
Ku et al. Retinal gene therapy: current progress and future prospects
Xia et al. Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
WO2023215546A3 (en) Adeno-associated virus compositions having increased brain enrichment
JP2024105661A (ja) 眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療
JPWO2022076711A5 (enExample)
HRP20241483T1 (hr) Sastavi i postupci za liječenje poremećaja mrežnice
IL312657A (en) Codon-optimised complement factor i
Colella et al. AAV-mediated gene supply for treatment of degenerative and neovascular retinal diseases